1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Selective Estrogen Receptor Modulators: new trials by email Literature Review of Selective Estrogen Receptor Modulators trials Research Report on Selective Estrogen Receptor Modulators
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Everolimus, Elacestrant, Placebo - Advanced Breast Cancer, ER-positive Breast Cancer | Phase 3 | Recruiting | MedSIR | 300 | 2024-12-05 | 2026-08-24 |
MedSIR (1)
Austria (1) · Brazil (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Spain (1) · United Kingdom (1)